ArticleFrontiers in molecular biosciences2026
Diagnostic and short-term prognosis value of serum ox-LDL/LOX-1 and GDF-15 in elderly patients with acute coronary syndrome.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the diagnosis and short-term prognosis of elderly patients with acute coronary syndrome (ACS), there has been a persistent lack of effective biomarkers. This study aimed to investigate the expression characteristics of serum oxidized-low-density lipoprotein (ox-LDL), lectin-like-oxidized low-density-lipoprotein receptor-1 (LOX-1), and growth-differentiation-factor 15 (GDF-15) in elderly ACS patients and assess their short-term prognostic value. Methods: 161 elderly patients with ACS and 66 elderly patients with non-ACS were enrolled. Subgroup classification included the ST-elevation myocardial infarction (STEMI), unstable-angina-pectoris (UAP) and NSTEMI. Serum ox-LDL, LOX-1 and GDF-15 were evaluated via ELISA assay. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic value. The prognosis of ACS patients was determined by Major-Adverse-Cardiovascular-Events (MACE) as the outcome. The short-term prognosis value of 3 serum biomarkers was evaluated using multivariate logistic analysis. Results: Ox-LDL, LOX-1, and GDF-15 levels in serum were significantly higher in elderly patients with ACS (all Conclusion: High serum GDF-15 levels are significantly associated with the presence of ACS and, in ACS patients, are significantly higher in those who do develop MACE. Serum GDF-15 can serve as an independent predictor of short-term MACE risk in elderly patients with ACS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.